Literature DB >> 24590481

Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.

Ruben C Hartkoorn1, Swapna Uplekar, Stewart T Cole.   

Abstract

The antileprosy drug clofazimine is also of interest for the treatment of multidrug-resistant tuberculosis. To understand possible resistance mechanisms, clofazimine-resistant Mycobacterium tuberculosis mutants were isolated in vitro, and, unexpectedly, found to be cross-resistant to bedaquiline. Mutations in the transcriptional regulator Rv0678, with concomitant upregulation of the multisubstrate efflux pump, MmpL5, accounted for this cross-resistance. Mutation in Rv0678 should therefore be considered a confounding factor for the treatment of tuberculosis with clofazimine or bedaquiline.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24590481      PMCID： PMC3993252          DOI： 10.1128/AAC.00037-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.

Authors:  Armand Van Deun; Aung Kya Jai Maug; Md Abdul Hamid Salim; Pankaj Kumar Das; Mihir Ranjan Sarker; Paul Daru; Hans L Rieder
Journal:  Am J Respir Crit Care Med       Date:  2010-05-04       Impact factor: 21.405

2.  A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Authors:  Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier
Journal:  Science       Date:  2004-12-09       Impact factor: 47.728

3.  Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Authors:  Kathy Williams; Austin Minkowski; Opokua Amoabeng; Charles A Peloquin; Dinesh Taylor; Koen Andries; Robert S Wallis; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

4.  Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Authors:  A H Diacon; P R Donald; A Pym; M Grobusch; R F Patientia; R Mahanyele; N Bantubani; R Narasimooloo; T De Marez; R van Heeswijk; N Lounis; P Meyvisch; K Andries; D F McNeeley
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

5.  Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance.

Authors:  Pilar Domenech; Michael B Reed; Clifton E Barry
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

6.  Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species.

Authors:  Takahiro Yano; Sacha Kassovska-Bratinova; J Shin Teh; Jeffrey Winkler; Kevin Sullivan; Andre Isaacs; Norman M Schechter; Harvey Rubin
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

7.  Analysis of the proteome of Mycobacterium tuberculosis in silico.

Authors:  F Tekaia; S V Gordon; T Garnier; R Brosch; B G Barrell; S T Cole
Journal:  Tuber Lung Dis       Date:  1999

8.  Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system.

Authors:  Anna Milano; Maria Rosalia Pasca; Roberta Provvedi; Anna Paola Lucarelli; Giulia Manina; Ana Luisa de Jesus Lopes Ribeiro; Riccardo Manganelli; Giovanna Riccardi
Journal:  Tuberculosis (Edinb)       Date:  2008-10-11       Impact factor: 3.131

9.  Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor.

Authors:  E Huitric; P Verhasselt; A Koul; K Andries; S Hoffner; D I Andersson
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

10.  Towards a new combination therapy for tuberculosis with next generation benzothiazinones.

Authors:  Vadim Makarov; Benoit Lechartier; Ming Zhang; João Neres; Astrid M van der Sar; Susanne A Raadsen; Ruben C Hartkoorn; Olga B Ryabova; Anthony Vocat; Laurent A Decosterd; Nicolas Widmer; Thierry Buclin; Wilbert Bitter; Koen Andries; Florence Pojer; Paul J Dyson; Stewart T Cole
Journal:  EMBO Mol Med       Date:  2014-02-05       Impact factor: 12.137
View more
  131 in total

1.  In Vitro Study of Stepwise Acquisition of rv0678 and atpE Mutations Conferring Bedaquiline Resistance.

Authors:  Shaheed V Omar; Remco P H Peters; Nabila Ismail; Nazir A Ismail
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  First use of bedaquiline in a patient with XDR-TB in Singapore.

Authors:  Angeline Poh-Gek Chua; Grace Si-Ru Hoo; Cynthia Bin-Eng Chee; Yee Tang Wang
Journal:  BMJ Case Rep       Date:  2015-09-23

3.  In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.

Authors:  Yu Pang; Zhaojing Zong; Fengmin Huo; Wei Jing; Yifeng Ma; Lingling Dong; Yunxu Li; Liping Zhao; Yuhong Fu; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

4.  Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis.

Authors:  Shuo Zhang; Jiazhen Chen; Peng Cui; Wanliang Shi; Wenhong Zhang; Ying Zhang
Journal:  J Antimicrob Chemother       Date:  2015-06-04       Impact factor: 5.790

5.  A Multimethod, Multicountry Evaluation of Breakpoints for Bedaquiline Resistance Determination.

Authors:  Koné Kaniga; Shaheed V Omar; Nazir Ahmed Ismail; Akio Aono; Emanuele Borroni; Daniela Maria Cirillo; Christel Desmaretz; Rumina Hasan; Satoshi Mitarai; Sadia Shakoor; Gabriela Torrea
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 6.  Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions.

Authors:  Gregory M Cook; Kiel Hards; Elyse Dunn; Adam Heikal; Yoshio Nakatani; Chris Greening; Dean C Crick; Fabio L Fontes; Kevin Pethe; Erik Hasenoehrl; Michael Berney
Journal:  Microbiol Spectr       Date:  2017-06

7.  Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.

Authors:  Suha Kadura; Nicholas King; Maria Nakhoul; Hongya Zhu; Grant Theron; Claudio U Köser; Maha Farhat
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

8.  Clofazimine for the Treatment of Mycobacterium kansasii.

Authors:  Shashikant Srivastava; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

9.  Structure-Function Profile of MmpL3, the Essential Mycolic Acid Transporter from Mycobacterium tuberculosis.

Authors:  Juan Manuel Belardinelli; Amira Yazidi; Liang Yang; Lucien Fabre; Wei Li; Benoit Jacques; Shiva Kumar Angala; Isabelle Rouiller; Helen I Zgurskaya; Jurgen Sygusch; Mary Jackson
Journal:  ACS Infect Dis       Date:  2016-09-01       Impact factor: 5.084

10.  Drug susceptibility distributions of Mycobacterium chimaera and other non-tuberculous mycobacteria.

Authors:  Bettina Schulthess; Daniel Schäfle; Nicole Kälin; Tamara Widmer; Peter Sander
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.